Fulvestrant in breast cancer: also a good option in triple-positive breast cancer | Zendy

Roberto López | Zendy; I. Delgado Sillero | Zendy; M. López Flores | Zendy; Laura López-González | Zendy; Andrés García Palomo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fulvestrant in breast cancer: also a good option in triple-positive breast cancer

Author(s) -

Roberto López,

I. Delgado Sillero,

M. López Flores,

Laura López-González,

Andrés García Palomo

Publication year - 2017

Publication title -

breast cancer management

Language(s) - English

Resource type - Journals

eISSN - 1758-1931

pISSN - 1758-1923

DOI - 10.2217/bmt-2017-0012

Subject(s) - fulvestrant , medicine , breast cancer , oncology , metastatic breast cancer , cancer , gynecology , estrogen receptor

Fulvestrant is indicated in the treatment of locally advanced or metastatic breast cancer in postmenopausal women with hormone receptor-positive breast cancer as second line at the present time, after first line hormone therapy. We present here a case report of a 47-year-old woman diagnosed with infiltrating ductal carcinoma left breast cancer in 1998, stage II, luminal B HER2-positive and a liver and ganglionar relapse 3 years later. After radical treatment, fulvestrant was indicated. She has been 10 years with this treatment, with an excellent tolerance and without showing progression until now.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research